Related Experiment Videos
[Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant
Abstract:
The inhibitory effect of difluoromethylornithine (DFMO) synthesized by the authors on the activity of the ornithine decarboxylase (ODC) and proliferation of microbial and mammalian cells in vitro was studied. The in vivo growth of ascite plasmocytoma of solid melanoma B-16 cells in mice was also effectively inhibited by DFMO. But the antiproliferative activity of DFMO in solid tumours was substantially lower. Such a decrease in the antitumour activity may be associated with polyamines released from necrotic areas of solid tumours. As the tumour cells "catch" the vitally important metabolites, their effect inside solid tumours is turned against the tumour cells themselves. The second reason of the decrease in the DFMO activity is adsorption of polyamines on the erythrocyte surface.
Insights
Difluoromethylornithine (DFMO) effectively inhibits microbial and mammalian cell proliferation and in vivo tumor growth. However, its antiproliferative activity is lower in solid tumors due to polyamine release and adsorption.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Ornithine decarboxylase (ODC) is a key enzyme in polyamine biosynthesis.
- Polyamines are essential for cell growth and proliferation.
- Difluoromethylornithine (DFMO) is a known inhibitor of ODC.
Purpose of the Study:
- To investigate the inhibitory effects of synthesized DFMO on ODC activity and cell proliferation.
- To evaluate the in vivo efficacy of DFMO against ascite plasmocytoma and solid melanoma B-16 in mice.
Main Methods:
- In vitro studies on microbial and mammalian cell lines.
- In vivo studies using mouse models with ascite plasmocytoma and solid melanoma B-16.
- Analysis of DFMO's antiproliferative activity and potential mechanisms of resistance.
Main Results:
- DFMO effectively inhibited ODC activity and cell proliferation in vitro.
- DFMO demonstrated significant inhibition of ascite plasmocytoma and melanoma B-16 growth in vivo.
- A reduced antiproliferative effect of DFMO was observed in solid tumors compared to ascites models.
Conclusions:
- DFMO is a potent inhibitor of ODC and exhibits significant anticancer activity.
- The reduced efficacy of DFMO in solid tumors may be attributed to polyamine release from necrotic areas and adsorption onto erythrocytes.
- Further research is warranted to overcome resistance mechanisms and optimize DFMO therapy for solid tumors.